

Should We Expand the Toolbox of Psychiatric Treatment Methods to Include Repetitive Transcranial Magnetic Stimulation (rTMS)? A Meta-Analysis of the Efficacy of rTMS in Psychiatric Disorders

Christina W. Slotema, MD; Jan Dirk Blom, MD, PhD;
Hans W. Hoek, MD, PhD; and Iris E. C. Sommer, MD, PhD

Objective: Repetitive transcranial magnetic stimulation (rTMS) is a safe treatment method with few side effects. However, efficacy for various psychiatric disorders is currently not clear.

Data sources: A literature search was performed from 1966 through October 2008 using PubMed, Ovid Medline, Embase Psychiatry, Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews, Database of Abstracts of Reviews of Effects, and PsycINFO. The following search terms were used: *transcranial magnetic stimulation, TMS, repetitive TMS, psychiatry, mental disorder, psychiatric disorder, anxiety disorder, attention-deficit hyperactivity disorder, bipolar disorder, catatonia, mania, depression, obsessive-compulsive disorder, psychosis, posttraumatic stress disorder, schizophrenia, Tourette's syndrome, bulimia nervosa, and addiction.*

Study selection: Data were obtained from randomized, sham-controlled studies of rTMS treatment for depression (34 studies), auditory verbal hallucinations (AVH, 7 studies), negative symptoms in schizophrenia (7 studies), and obsessive-compulsive disorder (OCD, 3 studies). Studies of rTMS versus electroconvulsive treatment (ECT, 6 studies) for depression were meta-analyzed.

Data extraction: Standardized mean effect sizes of rTMS versus sham were computed based on pretreatment-posttreatment comparisons.

Data synthesis: The mean weighted effect size of rTMS versus sham for depression was 0.55 ($P < .001$). Monotherapy with rTMS was more effective than rTMS as adjunctive to antidepressant medication. ECT was superior to rTMS in the treatment of depression (mean weighted effect size -0.47 , $P = .004$). In the treatment of AVH, rTMS was superior to sham treatment, with a mean weighted effect size of 0.54 ($P < .001$). The mean weighted effect size for rTMS versus sham in the treatment of negative symptoms in schizophrenia was 0.39 ($P = .11$) and for OCD, 0.15 ($P = .52$). Side effects were mild, yet more prevalent with high-frequency rTMS at frontal locations.

Conclusions: It is time to provide rTMS as a clinical treatment method for depression, for auditory verbal hallucinations, and possibly for negative symptoms. We do not recommend rTMS for the treatment of OCD.

J Clin Psychiatry 2010;71(7):873–884

© Copyright 2010 Physicians Postgraduate Press, Inc.

The first modern transcranial magnetic stimulation (TMS) device was developed during the early 1980s by Barker et al.^{1,2} The device creates a strong pulse of electrical current which is sent through a coil and which induces a magnetic field pulse in a small area underlying the coil. When applied over the skull, this pulse has the capacity to depolarize local neurons up to a depth of 2 cm. TMS can be used as a brain-mapping tool, as a tool to measure cortical excitability, as a probe of neuronal networks, and as a modulator of brain function. When repetitive TMS (rTMS) pulses are applied, a longer lasting effect can be induced which is thought to result from a long-term potentiation or depression at the neuronal level.³ High frequent rTMS can induce an epileptic seizure, which is a dangerous side effect. However, since the introduction of specific safety guidelines, rTMS is considered a safe treatment method.⁴ Its side effects are generally mild. They include headache, local discomfort as a consequence of direct stimulation of the facial musculature, and transient changes in the auditory threshold. To prevent this latter side effect, the use of earplugs is recommended.⁵ Initially, rTMS was investigated chiefly as a tool for the treatment of depression.⁶ A few years later, it was explored by Hoffman and colleagues⁷ for the treatment of auditory verbal hallucinations (AVH). Further research with rTMS has involved the experimental treatment of mood disorders, negative symptoms of schizophrenia, obsessive-compulsive disorder (OCD), Tourette's syndrome, posttraumatic stress disorder, panic disorder, Alzheimer's disease, bulimia nervosa, conversion, catatonia, and various forms of substance addiction.

Twenty-three years after its introduction, the number of publications reporting on the effects of rTMS treatment in psychiatric disorders has increased dramatically (263 published studies between 2000 and June 2008, as compared to 26 between 1990 and 2000). This 10-fold increase in the number of publications was accompanied by an even larger increase in sample size, which developed from single cases to samples of over 100 patients in recent publications.^{8,9} Furthermore, the US Food and Drug Administration approved rTMS for the treatment of depression in October 2008.

Due to its mild side effects and its relatively low costs, rTMS tends to be considered an attractive therapeutic tool. The TMS equipment can be obtained at the price of approximately €25,000, and the stimulation technique is relatively easy to acquire. However, mental health professionals may hesitate to embrace rTMS as a routine treatment method because its efficacy is as yet uncertain. A number of

Submitted: November 13, 2008; **accepted** February 2, 2009.

Online ahead of print: March 9, 2010 (doi:10.4088/JCP.08m04872gre).

Corresponding author: Christina W. Slotema, MD, Lijnbaan 4, 2512 VA, The Hague, the Netherlands (c.slotema@psyq.nl).

meta-analyses quantified the effects of rTMS for depressive disorder, but even these results are ambiguous.^{10–15} As the effect sizes of these studies differed substantially, no general conclusions can be drawn. More details are presented in the Discussion. The effects of rTMS treatment in AVH has been meta-analyzed once before, indicating a moderate mean effect size.¹⁶ No meta-analyses have been published on the effects of rTMS for other psychiatric disorders or symptom clusters. According to Loughlin et al¹⁷ and Kozel et al,¹⁸ the mean costs of an rTMS treatment for depression, consisting of 15 treatment sessions, are £1,444 and \$1,422, respectively. The duration of the effect of rTMS is as yet unknown, but for an effect of 4 months,¹⁹ the mean costs of antidepressant agents for the same period lie around \$110. The question remains whether patients benefiting from medication are comparable with patients having rTMS treatment. In our opinion, the data currently available do not allow for any firm conclusions about the costs of rTMS versus medication.

This review aims to assess the value of rTMS as a therapeutic tool for psychiatric disorders and for individual psychiatric symptoms.

METHOD

Study Selection

A literature search was performed using PubMed 1990 through October 2008, Ovid Medline 1990 through October 2008, Embase Psychiatry 1997 through October 2008, Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews, Database of Abstracts of Reviews of Effects, and PsycINFO 1990 through October 2008.

The following search terms were used: *transcranial magnetic stimulation, TMS, repetitive TMS, psychiatry, mental disorder, psychiatric disorder, anxiety disorder, attention-deficit hyperactivity disorder, bipolar disorder, catatonia, mania, depression, obsessive-compulsive disorder, psychosis, posttraumatic stress disorder, schizophrenia, Tourette's syndrome, bulimia nervosa, and addiction.*

The following criteria for inclusion were used:

1. Treatment with repetitive TMS.
2. Symptom severity of a psychiatric disorder is used as an outcome measure, and the psychiatric disorder being diagnosed in accordance with *DSM* and/or *ICD* criteria.
3. No specific “narrow” diagnosis or subgroup, such as depression after stroke or vascular depression
4. The study was performed in a parallel, double-blind, randomized controlled parallel design using a sham condition; an exception was made to the criterion “double-blind” for studies comparing rTMS with ECT, which cannot be blinded. We chose for parallel designs only, because patients cannot remain blinded in crossover studies, which may influence the results.
5. The data were sufficient to compute Hedges’ *g* (sample size, means, and standard deviations or exact *t* or *P* values for rTMS main effect for change scores).

6. At least 3 studies per psychiatric disorder/symptom cluster.
7. More than 3 patients per study.
8. Articles written in English. When various articles described overlapping samples, the article with the largest sample size was included.

Data Extraction

The following data were acquired: number of treated patients, mean and standard deviation of the outcome measure at baseline and at the end of treatment (or exact *F* or *P* value), study design, and treatment parameters (type of coil used, localization of treatment, frequency, intensity, number of stimuli per session, and number of treatment sessions). Whenever publications contained insufficient or incomplete data, the authors in question were contacted and invited to send additional data so that their study could be included in the meta-analysis. All meta-analyses were checked for cross-references.

Effect Size Calculation

Effect sizes were calculated for the mean differences (sham treatment versus rTMS) of the pretreatment-posttreatment change in rating scales. The mean gain for each study was computed using Comprehensive Meta Analysis Version 2.0 (Biostat, Englewood, New Jersey) in a random effects model. After the computation of individual effect sizes for each study, meta-analytic methods were applied to obtain a combined, weighted effect size, Hedges’ *g*, for each psychiatric disorder or symptom. The means of separate studies were weighted according to sample size. A homogeneity statistic, I^2 ,²⁰ was calculated to test whether the studies could be taken to share a common population effect size. High I^2 statistic (ie, 30% or higher) indicates heterogeneity of the individual study effect sizes, which poses a limitation to a reliable interpretation of the results. Whenever significant heterogeneity was found, a moderator analysis was performed to investigate the potential moderating factors. We expected the effects of rTMS to vary substantially according to localization, frequency, number of stimuli, and treatment sessions; as a consequence, subanalyses were performed to investigate different treatment conditions. The parameters were correlated with Hedges’ *g* using Pearson’s correlations in SPSS version 12 (SPSS Inc, Chicago, Illinois).

In studies comparing 3 treatment conditions, the 2 actual treatments were compared separately with the sham condition. In a number of studies on depression, rTMS was started simultaneously with antidepressant drug therapy or compared with electroconvulsive therapy (ECT). The results of these studies are presented separately.

Because the effect size can be overestimated due to the omission of studies in which rTMS was not effective, the fail-safe number of studies was computed.²¹ This fail-safe number is an estimation of the number of missing studies that is needed to change the results of the meta-analysis to nonsignificant.

Side effects and dropouts are presented according to rTMS frequency and localization.

Table 1. Number of Included Studies and Reasons for Exclusion

Psychiatric Disorder	No. of RCTs Included in Meta-Analysis	Reasons for Exclusion of Other Studies	No. of Excluded Studies
Depression	40	No (randomized) sham condition	58
		Overlap	15
		Insufficient data	14
		Outcome no severity of psychiatric symptoms	9
		Not in English	8
		Crossover design	6
		Patient no. lower than 3	3
		Maintenance or second rTMS treatment	3
		Single-pulse TMS	2
		rTMS as add-on with ECT	1
		Vascular depression	1
Auditory verbal hallucinations	7	Overlap	4
		Crossover design	4
		Insufficient data	3
		rTMS maintenance therapy	4
		No sham condition	2
Negative symptoms of schizophrenia	7	Outcome not severity of psychiatric symptoms	2
		Insufficient data	4
		No sham condition	3
		Crossover design	1
		Outcome not severity of psychiatric symptoms	1
		Not in English	1
Obsessive-compulsive disorder	3	Overlap	1
		No sham condition	2
		Insufficient data	1
		Outcome not severity of psychiatric symptoms	1
Tourette's syndrome	2	Not in English	1
		Insufficient data	1
		Outcome not severity of psychiatric symptoms	1
Panic disorder	1	Not in English	1
Bulimia nervosa	1	Less than 3 studies for this disorder	
Mania	1	No sham condition	2
Posttraumatic stress disorder	1	No sham condition	2
Cigarette addiction		Insufficient data	1
		Not in English	1
Alzheimer's disease		Insufficient data	1
		Crossover design	1
Cocaine addiction		No sham condition	1
Motor conversion		Patient no. < 3	1
Catatonia		Case reports	2

Abbreviations: ECT = electroconvulsive therapy, RCT = randomized controlled trial, rTMS = repetitive transcranial magnetic stimulation, TMS = transcranial magnetic stimulation.

RESULTS

The following disorders and individual symptoms were included in the meta-analysis: depression (40 studies), AVH (7 studies), negative symptoms of schizophrenia (7 studies), and OCD (3 studies) (Table 1). One hundred sixty-nine studies were excluded from the meta-analysis (for reasons for exclusion, see Table 1). No meta-analysis could be performed on rTMS for the treatment of Tourette's syndrome, panic disorder, posttraumatic stress disorder, mania, and bulimia nervosa, due to the small number of studies, ie, < 3. None of the studies concerning attention-deficit hyperactivity disorder, somatoform disorder, Alzheimer's disease, addiction, and catatonia fulfilled the stated criteria for inclusion.

Repetitive TMS in the Treatment of Depression

Forty studies were included in the meta-analysis. The studies were divided into 2 groups: rTMS versus sham (34 studies) and rTMS versus ECT (6 studies).

rTMS versus sham in the treatment of depression.

Thirty-four studies fulfilled the criteria for inclusion in the meta-analysis.^{8,9,22-53} The studies and treatment parameters are listed in Table 2. Seven hundred fifty-one patients were randomly assigned to rTMS treatment and 632 patients for the sham condition. Patients were free of antidepressant agents in 7 studies, antidepressant agents were continued during rTMS in 17 studies, and rTMS was started simultaneously with an antidepressant agent in 5 studies. Results of the meta-analysis are shown in Figure 1.

Effect sizes were computed for each study and weighted according to sample size. The mean weighted effect size for all studies comparing rTMS with sham treatment was 0.55 ($P < .001$). I^2 was 54% ($P < .001$). The fail-safe number was 18,462 studies. Since heterogeneity was high, moderator analyses were performed for the different stimulation parameters. When correlating the individual effect sizes of the studies to stimulation parameters, such as localization, frequency, intensity (percentage of motor threshold), number of stimuli per session, total number of stimuli, and number

Table 2. rTMS Parameters in the Treatment of Depression^a

Study	Location	Frequency, Hz	Motor Threshold, %	No. of Stimuli	No. of Sessions
O'Reardon et al, ⁸ 2007	L DLPF	10	120	3,000	25
Herwig et al, ⁹ 2007	L DLPF	10	110	2,000	15
Mogg et al, ²² 2008	L DLPF	10	110	1,000	10
Anderson et al, ²³ 2007	L DLPF	10	110	1,000	12
Bortolomasi et al, ²⁴ 2007	L DLPF	20	90	800	5
Koerselman et al, ²⁵ 2004	L DLPF	20	80	800	10
Fitzgerald et al, ²⁶ 2008	R DLPF	6 and 1	110	1,500	10
Loo et al, ²⁷ 2007	L DLPF	10	110	1,500	10
Stern et al, ²⁸ 2007	L DLPF	10	110	1,600	10
	L DLPF	1	110	1,600	10
	R DLPF	1	110	1,600	10
Fitzgerald et al, ²⁹ 2006	L and R DLPF	10 and 1	100 and 110	750 and 420	10
Garcia-Toro et al, ³⁰ 2006	LR DLPF	20 and 1	110	1,800 and 1,200	10
	L and R DLPF, PET	20 and 1	110	1,800 and 1,200	10
	R DLPF	1	90	120	16
Janual et al, ³¹ 2006	R DLPF	1	90	120	16
Su et al, ³² 2005	L DLPF	20	100	1,600	10
	L DLPF	5	100	1,600	10
	L DLPF	10	90	2,000	15
Buchholtz Hansen et al, ³³ 2004	L DLPF	10	110	1,600	10
Holtzheimer et al, ³⁴ 2004	L DLPF	10	110	1,600	10
Kauffmann et al, ³⁵ 2004	R DLPF	1	110	120	10
Mosimann et al, ³⁶ 2004	L DLPF	20	100	1,600	10
Fitzgerald et al, ³⁷ 2003	L DLPF	10	100	100	10
	R DLPF	1	100	300	10
Herwig et al, ³⁸ 2003	L or R DLPF, PET	15	110	3,000	10
Hoppner et al, ³⁹ 2003	L DLPF	20	90	400	10
	R DLPF	1	110	120	10
	LR DLPF	15	90	1,800	15
Loo et al, ⁴⁰ 2003	LR DLPF	15	90	1,800	15
Boutros et al, ⁴¹ 2002	L DLPF	20	80	800	10
Garcia-Toro et al, ⁴² 2001	L DLPF	20	90	1,200	10
Manes et al, ⁴³ 2001	L DLPF	20	80	800	5
Berman et al, ⁴⁴ 2000	L DLPF	20	80	800	10
George et al, ⁴⁵ 2000	L DLPF	20	100	1,600	10
	L DLPF	5	100	1,600	10
Avery et al, ⁴⁶ 1999	L DLPF	10	80	1,000	10
Klein et al, ⁴⁷ 1999	R DLPF	1	110	120	10
Loo et al, ⁴⁸ 1999	L DLPF	10	110	1,500	10
Padberg et al, ⁴⁹ 1999	L DLPF	0.3	90	250	5
	L DLPF	10	90	250	5
Rossini et al, ⁵⁰ 2005	L DLPF	15	100	900	10
Haussmann et al, ⁵¹ 2004	L DLPF and half R	20	100	2,000	10
Poulet et al, ⁵² 2004	L DLPF	10	80	400	10
Garcia-Toro et al, ⁵³ 2001	L DLPF	20	90	1,200	10

^aParameters are localization, frequency, motor threshold, stimuli per session, and number of sessions.


Abbreviations: DLPF = dorso-lateral prefrontal cortex, L = left, LR = bilateral, PET = positron emission tomography, R = right.

of sessions, no significant correlations emerged (P value between .38 and .95). The mean effect size for rTMS applied at the left dorso-lateral prefrontal cortex (DLPF) was 0.53 ($P < .001$); for rTMS directed to the right DLPF, it was 0.82 ($P < .001$); and for rTMS applied to both left and right DLPF (not simultaneously), it was 0.47 ($P = .03$). Mean Hedges' g for rTMS focused on the left or right DLPF was not statistically different from rTMS to the right DLPF ($t = -9.66$, $P = .34$). Another reason for heterogeneity was the variation in inclusion criteria. We calculated whether rTMS as a monotherapy was more effective than rTMS started simultaneously with antidepressant medication or during continuation of preexisting antidepressant treatment. The mean weighted effect sizes for rTMS as a monotherapy was 0.96 ($P < .001$) ($I^2 = 81\%$, $P < .001$); for rTMS with continuation of an antidepressant agent, it was 0.51 ($P < .001$) ($I^2 = 32\%$, $P = .08$); and for rTMS started simultaneously with an antidepressant agent, it was 0.37 ($P = .03$) ($I^2 = 44\%$, $P = .13$). The difference in efficacy between rTMS as a monotherapy and rTMS with continuation of an antidepressant

agent was marginally significant in favor of rTMS as a monotherapy ($t = 2.12$, $P = .06$). There was a trend for rTMS being more effective as a monotherapy than as an adjunctive to priorly started antidepressant agents ($t = 1.747$, $P = .09$). There was homogeneity if studies with rTMS as a monotherapy were excluded ($I^2 = 23.9$, $P = .11$); Hedges' g became 0.46 ($P < .001$). No difference between baseline mean severity scores for these 3 groups could be found ($t = 9.34$, $P = .36$), thus ruling out severity as a confounding factor. In a minority of studies (6 studies), patients with psychotic features were explicitly excluded. These studies yielded a better effect of rTMS than studies that did not use this exclusion criterion ($t = .128$, $P = .04$).

Reported side effects and dropouts for rTMS delivered at high frequency, and for sham treatment are presented in Tables 3 and 4. Reports of frequent headache, scalp discomfort, facial twitching, tearfulness, local erythema, and drowsiness were mentioned. Side effects occurred more often in high-frequency than in low-frequency rTMS.

Figure 1. rTMS for Depression, Results of the Meta-Analysis



^aAdd-on therapy.
Abbreviation: rTMS = repetitive transcranial magnetic stimulation.

rTMS versus ECT in the treatment of depression. ECT is a potent intervention in the treatment of depression, but complications associated with anesthesia,⁵⁴ cardiac risks, and memory disturbances are disadvantages⁵⁵ that are absent in rTMS treatment. For this reason, 6 additional studies were analyzed in which rTMS was compared with ECT in a randomized fashion.⁵⁶⁻⁶¹ A total of 215 patients were included in the meta-analysis, among which 113 were treated with rTMS, and 102 with ECT. The parameters of the rTMS treatment conditions are presented in Table 5. ECT consisted of unilateral and/or bilateral treatment at a frequency of 2 or 3 times a week.

The results of the meta-analysis are presented in Figure 2. Analysis showed that ECT yields more favorable results than rTMS, with a weighted effect size of -0.47 ($P = .004$).

Heterogeneity was moderately low: $I^2 = 28\%$, $P = .23$. The fail-safe number for these studies was 106 studies. See Tables 3 and 4 for side effects and dropouts.

rTMS in the Treatment of AVH

Seven randomized controlled trials were included in the meta-analysis, with a total number of 189 patients, of which 105 received rTMS treatment and 84, sham treatment.^{19,62-67} The parameters of the rTMS treatments are presented in Table 6.

In 7 studies, rTMS treatment was applied to the left temporoparietal cortex (ie, T3P3, according to Electroencephalogram Electrodes, Wernicke's area), and in 1 study to its right-sided homolog. The results of the meta-analysis are presented in Figure 3.

Table 3. Side Effects of rTMS Treatment Occurring in at Least 1% of the Participants per Indication

Side Effect	High-Frequency DLFP, n (%)	Low-Frequency DLFP, n (%)	Low-Frequency Temporoparietal, n (%)	Sham, n (%)
Depression				
Headache	46 (9.7)	4 (3.7)	...	12 (2.5)
Scalp discomfort	45 (9.3)	2 (1.8)	...	9 (1.9)
Facial twitching	9 (1.9)	5 (4.6)	...	0
Tearfulness	7 (1.5)	0	...	0
Local erythema	6 (1.3)	0	...	0
Drowsiness	12 (2.5)	0	...	0
Other	22 (4.7)	1 (0.9)	...	11 (2.4)
Total	145/472 (30.7)	12/109 (11)	...	32/461 (6.9)
Auditory verbal hallucinations				
Headache	6 (5.7)	2 (1.9)
Dizziness	2 (1.9)	1 (0.9)
Amnesia	1 (1.9)	0
Other	0	1 (0.9)
Total	9/105 (8.6)	4/108 (3.7)
Negative symptoms of schizophrenia				
Headache	6 (10.3)	2 (12.5)	...	1 (1.4)
Scalp discomfort	5 (8.6)	0	...	1 (1.4)
Facial twitching	0	3 (25)	...	0
Increase of akathisia	0	1 (6.3)	...	0
Increase of OCD symptoms	0	1 (6.3)	...	0
Total	11/58 (19)	7/16 (43.8)	...	2/74 (2.7)
OCD				
Headache	7 (70)	1 (3.6)	...	1 (3.6)
Scalp discomfort	12	0	...	0
Dizziness/fainting	3 (30)	0	...	1 (3.6)
Tearfulness	2 (20)	0	...	0
Total	24/10	1/28 (3.6)	...	2/28 (7.1)
Total for all groups	180/540 (33.3)	20/153 (13.1)	9/105 (8.6)	40/696 (5.7)

Abbreviations: DLFP = dorso-lateral prefrontal cortex, OCD = obsessive-compulsive disorder, rTMS = repetitive transcranial magnetic stimulation.
Symbol: ... = not applicable.

The effect size of rTMS was 0.54 ($P < .001$), indicating a moderate effect. The percentage for heterogeneity was 0 ($P = .61$). Therefore, no additional moderator analysis was performed. The fail-safe number was 269 studies.

Side effects are described in Table 3. They occurred in 8.6% of the participants during rTMS treatment and in 3.9% during sham treatment. Reasons for dropout are listed in Table 4.

rTMS in the Treatment of Negative Symptoms of Schizophrenia

A meta-analysis of 7 studies was performed, with a total number of 148 participating patients, of which 74 received rTMS treatment, and an equal number sham treatment.⁶⁸⁻⁷⁴ Table 7 lists the parameters of rTMS in the treatment of negative symptoms of schizophrenia. Except for 1 study, the left DLFP served as the focus of treatment. Figure 4 shows details of the results of the meta-analysis. Hedges' g was 0.39 ($P = .11$). I^2 was 56% ($P = .03$). The fail-safe number was 13 studies. Because of the high heterogeneity a moderator analysis was performed; no significant correlation was found between individual effect sizes and rTMS parameters such as frequency, number of sessions, duration, percentage of the motor threshold, and total number of stimulations.

In Tables 3 and 4, side effects and dropouts are presented. Side effects occurred in 24% of the patients during rTMS treatment, compared to none during placebo treatment. They consisted of headache, scalp discomfort, facial

twitching, increase in akathisia, and increase in comorbid OCD symptoms.

Obsessive-Compulsive Disorder

Three articles were included in the meta-analysis of rTMS for the treatment of OCD, yielding a total number of 38 patients receiving rTMS and 28 receiving sham treatment.⁷⁵⁻⁷⁷ Details of the rTMS parameters are listed in Table 8.

Figure 5 displays the results of the meta-analysis. Hedges' g was 0.15 ($P = .52$), which is not significantly more favorable than sham treatment. The score for heterogeneity was 0 ($P = .89$), indicating no bias as a consequence of moderators. See Table 4 for an overview of the side effects, which consisted of headache, scalp discomfort, dizziness, and tearfulness. Dropouts did not occur.

DISCUSSION

This study provides a critical and quantitative summary of clinical studies using rTMS as a treatment method for psychiatric indications. It aims to formulate a carefully considered recommendation for psychiatric professionals whether or not to adopt this treatment method as a standard therapy. The literature includes ample high-quality studies to allow for meta-analyses of the efficacy of rTMS for depression, AVH, negative symptoms in schizophrenia, and OCD. We also meta-analyzed the efficacy of rTMS versus ECT in the treatment of depression.

Table 4. Reasons for Dropout

Reason	High-Frequency DLPF, n (%)	Low-Frequency DLPF, n (%)	Low-Frequency Temporoparietal, n (%)	Sham, n (%)
Depression				
Side effects	22 (4.7)	0	...	11 (2.3)
Worsening of symptoms	17 (3.6)	1 (0.9)	...	12 (2.5)
Other/unknown	11 (2.3)	8 (7.3)	...	26 (5.3)
Total	50/472 (10.6)	9/109 (8.3)	...	49/486 (10.1)
Auditory verbal hallucinations				
Side effects	2 (1.9)	1 (0.9)
Worsening of symptoms	0	3 (2.8)
Other/unknown	0	0
Total	2/105 (1.9)	4/108 (3.7)
Negative symptoms of schizophrenia				
Side effects	3 (5.2)	0	...	1 (1.4)
Worsening of symptoms	1 (1.7)	2 (7.1)	...	0
Other/unknown	1 (1.7)	0	...	3 (4.1)
Total	5/58 (8.6)	2 (7.1)	...	4/74 (5.4)
Obsessive-compulsive disorder				
Side effects	0	0	...	0
Worsening of symptoms	0	0	...	0
Other/unknown	0	0	...	0
Total	0	0	...	0
Total for all groups	55/540 (10.2)	11/165 (6.7)	2/105 (1.9)	57/696 (8.2)

Abbreviation: DLPF = dorso-lateral prefrontal cortex.

Table 5. rTMS Parameters for Depression Versus Electroconvulsive Therapy

Study	Location	Frequency, Hz	Motor Threshold, %	No. of Stimuli	No. of Sessions
Eranti et al, ⁵⁶ 2007	L DLPF	10	110	1,000	15
Rosa et al, ⁵⁷ 2006	L DLPF	10	110	2,500	20
Grunhaus et al, ⁵⁸ 2003	L DLPF	10	90	1,200	20
Janicak et al, ⁵⁹ 2002	L DLPF	10	110	1,500	15
Grunhaus et al, ⁶⁰ 2000	L DLPF	10	90	800	20
Pridmore ⁶¹ 2000	L DLPF	20	100	1,300	12

Abbreviations: DLPF = dorso-lateral prefrontal cortex, L = left, rTMS = repetitive transcranial magnetic stimulation.

The new information presented in this article is based primarily on the inclusion of the highest number of studies to date considering rTMS for depression, and the performance of subanalyses of rTMS as monotherapy, of rTMS as an adjunctive to antidepressant medication, and of rTMS started simultaneously with an antidepressant agent. This study provides more evidence that ECT is superior to rTMS in contrast to the previous meta-analysis by Burtin et al,¹¹ who found no significant difference between ECT and rTMS. Moreover, this is the first meta-analysis of rTMS as a treatment method for negative symptoms of schizophrenia and OCD.


Our results indicate that repetitive TMS is more effective than sham treatment in the treatment of depression, but less effective than ECT. rTMS is also effective for AVH in schizophrenia, even for AVH resistant to antipsychotic medication. We found a trend toward an effect of rTMS for negative symptoms in schizophrenia, but more studies are needed to confirm this finding. rTMS is not superior to sham treatment for the treatment of OCD. Thus it appears to be a

useful method in the treatment of common conditions such as depression and AVH. In addition, it is one of the very few treatment methods that may have some effect on negative symptoms of schizophrenia, although the evidence for this indication is currently insufficient. Findings for the different disorders are discussed in detail below.

rTMS for Depression

Repetitive TMS directed to the DLPF (either left or right) has a moderate mean effect size in the treatment of depression according to the results of 34 studies. In comparison with sham treatment, the highest effect size was found for studies using rTMS as monotherapy, followed by studies with rTMS as an adjunctive to continuation of pharmacotherapy. The analysis of 5 randomized controlled studies shows evidence for a small, but significant additional effect of rTMS when it is started simultaneously with pharmacotherapy. This lower effect of cotherapy as compared to monotherapy was not explained by a difference in baseline

Figure 2. Meta-Analysis of rTMS Versus ECT in the Treatment of Depression




Abbreviations: ECT = electroconvulsive therapy, rTMS = repetitive transcranial magnetic stimulation.

Table 6. rTMS Parameters for Auditory Verbal Hallucinations

Study	Location	Frequency, Hz	Motor Threshold, %	No. of Stimuli	No. of Sessions
Hoffman et al, ¹⁹ 2005	T3P3	1	90	900	10
Rosa et al, ⁶² 2007	T3P3	1	90	960	10
Brunelin et al, ⁶³ 2006	T3P3	1	90	1,000	10
Chibbaro et al, ⁶⁷ 2005	T3P3	1	90	900	4
Fitzgerald et al, ⁶⁴ 2005	T3P3	1	90	900	10
Lee et al, ⁶⁵ 2005	T3P3	1	100	1,600	10
	T4P4	1	100	1,600	10
Saba et al, ⁶⁶ 2004	T3P3	1	80	300	10

Abbreviation: rTMS = repetitive transcranial magnetic stimulation.

Figure 3. Results of the Meta-Analysis of rTMS in the Treatment of Auditory Verbal Hallucinations



Abbreviation: rTMS = repetitive transcranial magnetic stimulation.

depression severity or by differences in stimulation parameters. Rather, the different effect sizes may be due to variability in treatment resistance among the 3 treatment groups or to an additional effect following the withdrawal of medication. Furthermore, lower expectations and hope to benefit from this treatment could form an alternative explanation. Low-frequency right-sided rTMS showed a trend toward better response than high-frequency left-sided rTMS, but full statistical significance was not achieved. rTMS had a better effect in studies that explicitly excluded patients with psychotic depression, as compared to samples that did not exclude this patient group.

The mean effect size found for rTMS treatment in depression (ie, 0.55) is high when compared to effect sizes


commonly reported for pharmacotherapy in depression (ie, between 0.17 and 0.46).⁷⁸⁻⁸¹ Our results are in concordance with the meta-analysis of Schutter et al,¹⁵ who found an effect size of 0.39 in 30 studies. The established difference may be explained by the inclusion of only high-frequency rTMS treatments directed to the left DLPF in their meta-analysis. The effect sizes of 2 meta-analyses of 33 studies by Hermann et al^{14,82} were 0.65 and 0.59 respectively, which were comparable to our results, although those meta-analyses also included crossover studies. In a crossover design, patients cannot remain completely blind in the treatment condition, as actual rTMS produces loud clicks and twitching sensations in the skin that are difficult to mimic in a sham condition and may influence the results in favor of rTMS.

Table 7. rTMS Parameters in the Treatment of Negative Symptoms of Schizophrenia

Study	Location	Frequency, Hz	Motor Threshold, %	No. of Stimuli	No. of Sessions
Fitzgerald ⁶⁸ 2008	L and R DLPF	10	110	1,000	15
Mogg et al, ⁶⁹ 2007	L DLPF	10	110	2,000	10
Prikyl et al, ⁷⁰ 2007	L DLPF	10	110	1,500	15
Novak et al, ⁷¹ 2006	L DLPF	20	90	2,000	10
Hajak et al, ⁷² 2004	L DLPF	10	110	1,000	10
Holi et al, ⁷³ 2004	L DLPF	10	100	1,000	10
Klein et al, ⁷⁴ 1999	R DLPF	1	110	120	10

Abbreviations: DLPF = dorso-lateral prefrontal cortex, L = left, R = right, rTMS = repetitive transcranial magnetic stimulation.

Figure 4. Meta-Analysis of rTMS for Negative Symptoms of Schizophrenia




Abbreviation: rTMS = repetitive transcranial magnetic stimulation.

Table 8. Parameters of rTMS for Obsessive-Compulsive Disorder

Study	Location	Frequency, Hz	Motor Threshold, %	No. of Stimuli	No. of Sessions
Sachdev et al, ⁷⁵ 2007	L DLPF	10	110	1,500	10
Prasko et al, ⁷⁶ 2006	L DLPF	1	110	1,800	10
Alonso et al, ⁷⁷ 2001	R DLPF	1	110	1,200	18

Abbreviations: DLPF = dorso-lateral prefrontal cortex, L = left, R = right, rTMS = repetitive transcranial magnetic stimulation.

Figure 5. rTMS for Obsessive-Compulsive Disorder, Results of the Meta-Analysis



Abbreviation: rTMS = repetitive transcranial magnetic stimulation.

Burt et al¹¹ included studies with other conditions (such as high- versus low-frequency rTMS, and rTMS with anti-depressant agents, versus antidepressant agents alone) and found equal results for 16 studies with an effect size of 0.67. Holtzheimer et al¹⁰ meta-analyzed 12 studies, some of which used a crossover design, and found a large mean effect size of 0.81. Conversely, no effect was found in comparison with sham treatment in the meta-analysis by Couturier et al,¹³ in which only 6 trials were included due to stringent criteria for sham treatment, side of treatment, and statistical methods. Thirteen studies were analyzed by Martin et al,¹² showing a

significantly more favorable effect of rTMS focused on the left DLPF (standardized posttreatment difference of -0.35) as compared to sham treatment.

Our meta-analysis including 6 studies comparing rTMS for depression to ECT showed that rTMS cannot replace ECT, as patients improved significantly better with ECT. As only patients indicated for ECT participated in these studies, the majority had severe depression. Burt et al¹¹ also performed a meta-analysis of 3 studies comparing rTMS to ECT and found a nonsignificant difference in favor of ECT. The difference with our mean effect size (-0.47) is explained

by the inclusion of 3 more studies with negative effects in our analysis. Thus, when considering rTMS for depression, it appears to be more effective when given as a monotherapy. Depressive patients with psychotic symptoms may profit less from rTMS treatment, as the results of rTMS are less favorable than those of ECT.

Repetitive TMS for AVH

Meta-analysis shows a moderate effect of rTMS on the severity of AVH in 7 studies. Most studies include patients with medication-resistant AVH, indicating a group with intractable symptomatology. A mean effect size of 0.76 was found in a previous meta-analysis investigating rTMS for AVH by Aleman et al.¹⁶ This mean effect was higher than that of the current study (0.54), which may be due to the exclusion of crossover studies in our analysis. As patients with medication-resistant AVH have few other possibilities for treatment, we definitely recommend offering rTMS treatment for this group.

rTMS for Negative Symptoms of Schizophrenia

Following the results of 7 studies, rTMS directed at the DLPF may improve negative symptoms of schizophrenia compared to sham, but the number of included studies was too low to reach statistical significance. Given the mild side effect profile of rTMS and the current poverty of therapeutic options for negative symptoms, we recommend that rTMS may be attempted as a possibility to improve negative symptoms.

Repetitive TMS for OCD

For the treatment of OCD no significant effect of rTMS was found in the 3 included studies. In spite of the small number of studies, the results were homogeneous. This indicates that OCD is not a psychiatric indication for rTMS.

Tolerability

Side effects reported for different indications were headache, scalp discomfort, drowsiness, facial muscle twitching, tearfulness, dizziness, and nausea. All of these side effects were transient and mild and occurred more often with high-frequency than with low-frequency rTMS, and more often in rTMS directed to the DLPF than in rTMS to the temporoparietal areas. The percentage of dropouts was equal for rTMS and sham treatment, and lower for AVH and OCD than for depression and negative symptoms.

Limitations

Study numbers and patient samples were rather small in the meta-analyses for AVH, negative symptoms of schizophrenia and OCD. Another matter of concern is that half of the studies including patients with major depression and AVH selected patients who were “therapy resistant,” using varying definitions. This may have led to the selection of patients with refractory symptoms, which may in turn have lowered the success rate of rTMS. Secondly, several studies mentioned the number of dropouts but not the reasons for

it. It is important to know the reasons for dropout and the way the data on dropout were analyzed, since this may have affected the final results.

Although the efficacy of rTMS in the treatment of depression and AVH may be considered proven, the duration of the effect is as yet unknown. Effect sizes were measured immediately after the cessation of rTMS treatment. There are indications that the effect of rTMS may last for several weeks to months.^{19,22–25,67} Future studies should assess symptom relief with longer follow-up periods to assess the cost-effectiveness of rTMS treatment, and to indicate its economic advantages and disadvantages. A few case reports have described rTMS as maintenance therapy for AVH; long-term treatment with rTMS resulted in a marked improvement of AVH,^{83–87} but more studies are needed to decide which maintenance treatment strategy may yield the best results.

CONCLUSION

rTMS deserves a place in the standard toolbox of psychiatric treatment methods, as it is effective for depression and AVH and has a mild side effect profile. Although the working mechanism of rTMS has not been fully elucidated, it would seem to affect the central nervous system in a way that is fundamentally different from pharmacotherapy. This may well be the reason why it may be effective in patients who are resistant to medication, both in depression and in individuals suffering from AVH. A trend was observed toward efficacy of rTMS treatment of negative symptoms of schizophrenia. On the other hand, OCD patients appeared not to benefit from it. It is noteworthy that rTMS was more effective for depression when applied in the form of a monotherapy, which indicates that rTMS should not be regarded as an adjuvant treatment for this disorder. Although rTMS cannot replace ECT in depressive patients, there may be subgroups in which rTMS can replace antidepressant medication.

Author affiliations: Center for Personality Disorders (Dr Slotema), Department of Psychotic Disorders (Dr Blom), and Psychiatric Residency & Research (Dr Hoek), Parnassia Bavo Psychiatric Institute, the Hague; Department of Psychiatry, University of Groningen (Drs Blom and Hoek); Department of Psychiatry, University Medical Center Utrecht (Dr Sommer), the Netherlands; and Columbia University, New York, New York (Dr Hoek).

Potential conflicts of interest: None reported.

Funding/support: The study was supported by grants from NOW (Dutch Scientific Research Foundation), ZonMW (Dutch National Institutes of Health Research), and Stichting tot Steun (Dutch Support Foundation).

REFERENCES

1. Barker AT, Jalinous R, Freeston IL. Non-invasive magnetic stimulation of human motor cortex. *Lancet*. 1985;325(8437):1106–1107.
2. Barker AT, Freeston IL, Jarratt JA, et al. Magnetic stimulation of the human nervous system: an introduction and basic principles. In: Chokroverty S, ed. *Magnetic Stimulation in Clinical Neurophysiology*. Boston, MA: Butterworths; 1990:55–72.
3. Siebner HR, Rothwell J. Transcranial magnetic stimulation: new insights into representational cortical plasticity. *Exp Brain Res*. 2003;148(1):1–16.
4. Wassermann EM. Risk and safety of repetitive transcranial magnetic stimulation: report and suggested guidelines from the International Workshop on the Safety of Repetitive Transcranial Magnetic Stimulation, June 5–7, 1996. *Electroencephalogr Clin Neurophysiol*. 1998;108(1):1–16.

5. George MS, Belmaker RH. *Transcranial Magnetic Stimulation in Clinical Psychiatry*. Arlington, VA: American Psychiatric Publishing, Inc.; 2007.
6. George MS, Wassermann EM, Williams WA, et al. Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression. *Neuroreport*. 1995;6(14):1853–1856.
7. Hoffman RE, Boutros NN, Hu S, et al. Transcranial magnetic stimulation and auditory hallucinations in schizophrenia. *Lancet*. 2000;355(9209):1073–1075.
8. O'Reardon JP, Solvason HB, Janicak PG, et al. Efficacy and safety of transcranial magnetic stimulation in the acute treatment of major depression: a multisite randomized controlled trial. *Biol Psychiatry*. 2007;62(11):1208–1216.
9. Herwig U, Fallgatter AJ, Höppner J, et al. Antidepressant effects of augmentative transcranial magnetic stimulation: randomised multicentre trial. *Br J Psychiatry*. 2007;191(5):441–448.
10. Holtzheimer PE 3rd, Russo J, Avery DH. A meta-analysis of repetitive transcranial magnetic stimulation in the treatment of depression. *Psychopharmacol Bull*. 2001;35(4):149–169.
11. Burt T, Lisanby SH, Sackeim HA. Neuropsychiatric applications of transcranial magnetic stimulation: a meta analysis. *Int J Neuropsychopharmacol*. 2002;5(1):73–103.
12. Martin JL, Barbanj M, Schlaepfer TE, et al. Repetitive transcranial magnetic stimulation for the treatment of depression: systematic review and meta-analysis. *Br J Psychiatry*. 2003;182(>6):480–491.
13. Couturier JL. Efficacy of rapid-rate repetitive transcranial magnetic stimulation in the treatment of depression: a systematic review and meta-analysis. *J Psychiatry Neurosci*. 2005;30(2):83–90.
14. Herrmann LL, Ebmeier KP. Factors modifying the efficacy of transcranial magnetic stimulation in the treatment of depression: a review. *J Clin Psychiatry*. 2006;67(12):1870–1876.
15. Schutter DJ. Antidepressant efficacy of high-frequency transcranial magnetic stimulation over the left dorsolateral prefrontal cortex in double-blind sham-controlled designs: a meta-analysis. *Psychol Med*. 2009;39(1):65–75.
16. Aleman A, Sommer IE, Kahn RS. Efficacy of slow repetitive transcranial magnetic stimulation in the treatment of resistant auditory hallucinations in schizophrenia: a meta-analysis. *J Clin Psychiatry*. 2007;68(3):416–421.
17. McLoughlin DM, Mogg A, Eranti S, et al. The clinical effectiveness and cost of repetitive transcranial magnetic stimulation versus electroconvulsive therapy in severe depression: a multicentre pragmatic randomised controlled trial and economic analysis. *Health Technol Assess*. 2007;11(24):1–54.
18. Kozel FA, George MS, Simpson KN. Decision analysis of the cost-effectiveness of repetitive transcranial magnetic stimulation versus electroconvulsive therapy for treatment of nonpsychotic severe depression. *CNS Spectr*. 2004;9(6):476–482.
19. Hoffman RE, Gueorguieva R, Hawkins KA, et al. Temporoparietal transcranial magnetic stimulation for auditory hallucinations: safety, efficacy and moderators in a fifty patient sample. *Biol Psychiatry*. 2005;58(2):97–104.
20. Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. *BMJ*. 2003;327(7414):557–560.
21. Rosenthal R. The file drawer problem and tolerance for null results. *Psychol Bull*. 1979;86(3):638–641.
22. Mogg A, Pluck G, Eranti SV, et al. A randomized controlled trial with 4-month follow-up of adjunctive repetitive transcranial magnetic stimulation of the left prefrontal cortex for depression. *Psychol Med*. 2008;38(3):323–333.
23. Anderson IM, Delvai NA, Ashim B, et al. Adjunctive fast repetitive transcranial magnetic stimulation in depression. *Br J Psychiatry*. 2007;190(6):533–534.
24. Bortolomasi M, Minelli A, Fuggetta G, et al. Long-lasting effects of high frequency repetitive transcranial magnetic stimulation in major depressed patients. *Psychiatry Res*. 2007;150(2):181–186.
25. Koerselman F, Laman DM, van Duijn H, et al. A 3-month, follow-up, randomized, placebo-controlled study of repetitive transcranial magnetic stimulation in depression. *J Clin Psychiatry*. 2004;65(10):1323–1328.
26. Fitzgerald PB, Hoy K, McQueen S, et al. Priming stimulation enhances the effectiveness of low-frequency right prefrontal cortex transcranial magnetic stimulation in major depression. *J Clin Psychopharmacol*. 2008;28(1):52–58.
27. Loo CK, Mitchell PB, McFarquhar TE, et al. A sham-controlled trial of the efficacy and safety of twice-daily rTMS in major depression. *Psychol Med*. 2007;37(3):341–349.
28. Stern WM, Tormos JM, Press DZ, et al. Antidepressant effects of high and low frequency repetitive transcranial magnetic stimulation to the dorsolateral prefrontal cortex: a double-blind, randomized, placebo-controlled trial. *J Neuropsychiatry Clin Neurosci*. 2007;19(2):179–186.
29. Fitzgerald PB, Benitez J, de Castella A, et al. A randomized, controlled trial of sequential bilateral repetitive transcranial magnetic stimulation for treatment-resistant depression. *Am J Psychiatry*. 2006;163(1):88–94.
30. Garcia-Toro M, Salva J, Daumal J, et al. High (20-Hz) and low (1-Hz) frequency transcranial magnetic stimulation as adjuvant treatment in medication-resistant depression. *Psychiatry Res*. 2006;146(1):53–57.
31. Januel D, Dumortier G, Verdon CM, et al. A double-blind sham controlled study of right prefrontal repetitive transcranial magnetic stimulation (rTMS): therapeutic and cognitive effect in medication free unipolar depression during 4 weeks. *Prog Neuropsychopharmacol Biol Psychiatry*. 2006;30(1):126–130.
32. Su TP, Huang CC, Wei IH. Add-on rTMS for medication-resistant depression: a randomized, double-blind, sham-controlled trial in Chinese patients. *J Clin Psychiatry*. 2005;66(7):930–937.
33. Buchholtz Hansen PE, Videbeck P, Clemmensen K, et al. Repetitive transcranial magnetic stimulation as add-on antidepressant treatment. The applicability of the method in a clinical setting. *Nord J Psychiatry*. 2004;58(6):455–457.
34. Holtzheimer PE 3rd, Russo J, Claypoole KH, et al. Shorter duration of depressive episode may predict response to repetitive transcranial magnetic stimulation. *Depress Anxiety*. 2004;19(1):24–30.
35. Kauffmann CD, Cheema MA, Miller BE. Slow right prefrontal transcranial magnetic stimulation as a treatment for medication-resistant depression: a double-blind, placebo-controlled study. *Depress Anxiety*. 2004;19(1):59–62.
36. Mosimann UP, Schmitt W, Greenberg BD, et al. Repetitive transcranial magnetic stimulation: a putative add-on treatment for major depression in elderly patients. *Psychiatry Res*. 2004;126(2):123–133.
37. Fitzgerald PB, Brown TL, Marston NA, et al. Transcranial magnetic stimulation in the treatment of depression: a double-blind, placebo-controlled trial. *Arch Gen Psychiatry*. 2003;60(10):1002–1008.
38. Herwig U, Lampe Y, Juengling FD, et al. Add-on rTMS for treatment of depression: a pilot study using stereotaxic coil-navigation according to PET data. *J Psychiatr Res*. 2003;37(4):267–275.
39. Höppner J, Schulz M, Irmisch G, et al. Antidepressant efficacy of two different rTMS procedures: high frequency over left versus low frequency over right prefrontal cortex compared with sham stimulation. *Eur Arch Psychiatry Clin Neurosci*. 2003;253(2):103–109.
40. Loo CK, Mitchell PB, Croker VM, et al. Double-blind controlled investigation of bilateral prefrontal transcranial magnetic stimulation for the treatment of resistant major depression. *Psychol Med*. 2003;33(1):33–40.
41. Boutros NN, Gueorguieva R, Hoffman RE, et al. Lack of a therapeutic effect of a 2-week sub-threshold transcranial magnetic stimulation course for treatment-resistant depression. *Psychiatry Res*. 2002;113(3):245–254.
42. Garcia-Toro M, Mayol A, Arnillas H, et al. Modest adjunctive benefit with transcranial magnetic stimulation in medication-resistant depression. *J Affect Disord*. 2001;64(2–3):271–275.
43. Manes F, Jorge R, Morcuende M, et al. A controlled study of repetitive transcranial magnetic stimulation as a treatment of depression in the elderly. *Int Psychogeriatr*. 2001;13(2):225–231.
44. Berman RM, Narasimhan M, Sanacora G, et al. A randomized clinical trial of repetitive transcranial magnetic stimulation in the treatment of major depression. *Biol Psychiatry*. 2000;47(4):332–337.
45. George MS, Nahas Z, Molloy M, et al. A controlled trial of daily left prefrontal cortex TMS for treating depression. *Biol Psychiatry*. 2000;48(10):962–970.
46. Avery DH, Claypoole K, Robinson L, et al. Repetitive transcranial magnetic stimulation in the treatment of medication-resistant depression: preliminary data. *J Nerv Ment Dis*. 1999;187(2):114–117.
47. Klein E, Kreinin I, Chistyakov A, et al. Therapeutic efficacy of right prefrontal slow repetitive transcranial magnetic stimulation in major depression: a double-blind controlled study. *Arch Gen Psychiatry*. 1999;56(4):315–320.
48. Loo C, Mitchell P, Sachdev P, et al. Double-blind controlled investigation of transcranial magnetic stimulation for the treatment of resistant major depression. *Am J Psychiatry*. 1999;156(6):946–948.
49. Padberg F, Zwanzger P, Thoma H, et al. Repetitive transcranial magnetic stimulation (rTMS) in pharmacotherapy-refractory major depression: comparative study of fast, slow and sham rTMS. *Psychiatry Res*. 1999;88(3):163–171.
50. Rossini D, Magri L, Lucca A, et al. Does rTMS hasten the response to escitalopram, sertraline, or venlafaxine in patients with major depressive disorder? a double-blind, randomized, sham-controlled trial.

- J Clin Psychiatry*. 2005;66(12):1569–1575.
51. Hausmann A, Kemmler G, Walpoth M, et al. No benefit derived from repetitive transcranial magnetic stimulation in depression: a prospective, single centre, randomised, double blind, sham controlled “add on” trial. *J Neurol Neurosurg Psychiatry*. 2004;75(2):320–322.
 52. Poulet E, Brunelin J, Boeuvre C, et al. Repetitive transcranial magnetic stimulation does not potentiate antidepressant treatment. *Eur Psychiatry*. 2004;19(6):382–383.
 53. García-Toro M, Pascual-Leone A, Romera M, et al. Prefrontal repetitive transcranial magnetic stimulation as add on treatment in depression. *J Neurol Neurosurg Psychiatry*. 2001;71(4):546–548.
 54. Hooten WM, Rasmussen KG Jr. Effects of general anesthetic agents in adults receiving electroconvulsive therapy: a systematic review. *J ECT*. 2008;24(3):208–223.
 55. Crowley K, Pickle J, Dale R, et al. A critical examination of bifrontal electroconvulsive therapy: clinical efficacy, cognitive side effects, and directions for future research. *J ECT*. 2008;24(4):268–271.
 56. Eranti S, Mogg A, Pluck G, et al. A randomized, controlled trial with 6-month follow-up of repetitive transcranial magnetic stimulation and electroconvulsive therapy for severe depression. *Am J Psychiatry*. 2007;164(1):73–81.
 57. Rosa MA, Gattaz WF, Pascual-Leone A, et al. Comparison of repetitive transcranial magnetic stimulation and electroconvulsive therapy in unipolar non-psychotic refractory depression: a randomized, single-blind study. *Int J Neuropsychopharmacol*. 2006;9(6):667–676.
 58. Grunhaus L, Schreiber S, Dolberg OT, et al. A randomized controlled comparison of electroconvulsive therapy and repetitive transcranial magnetic stimulation in severe and resistant nonpsychotic major depression. *Biol Psychiatry*. 2003;53(4):324–331.
 59. Janicak PG, Dowd SM, Martis B, et al. Repetitive transcranial magnetic stimulation versus electroconvulsive therapy for major depression: preliminary results of a randomized trial. *Biol Psychiatry*. 2002;51(8):659–667.
 60. Grunhaus L, Dannon PN, Schreiber S, et al. Repetitive transcranial magnetic stimulation is as effective as electroconvulsive therapy in the treatment of nondelusional major depressive disorder: an open study. *Biol Psychiatry*. 2000;47(4):314–324.
 61. Pridmore S. Substitution of rapid transcranial magnetic stimulation treatments for electroconvulsive therapy treatments in a course of electroconvulsive therapy. *Depress Anxiety*. 2000;12(3):118–123.
 62. Rosa MO, Gattaz WF, Rosa MA, et al. Effects of repetitive transcranial magnetic stimulation on auditory hallucinations refractory to clozapine. *J Clin Psychiatry*. 2007;68(10):1528–1532.
 63. Brunelin J, Poulet E, Bediou B, et al. Low frequency repetitive transcranial magnetic stimulation improves source monitoring deficit in hallucinating patients with schizophrenia. *Schizophr Res*. 2006;81(1):41–45.
 64. Fitzgerald PB, Benitez J, Daskalakis JZ, et al. A double-blind sham-controlled trial of repetitive transcranial magnetic stimulation in the treatment of refractory auditory hallucinations. *J Clin Psychopharmacol*. 2005;25(4):358–362.
 65. Lee SH, Kim W, Chung YC, et al. A double blind study showing that two weeks of daily repetitive TMS over the left or right temporoparietal cortex reduces symptoms in patients with schizophrenia who are having treatment-refractory auditory hallucinations. *Neurosci Lett*. 2005;376(3):177–181.
 66. Saba G, Verdon CM, Kalalou K, et al. Transcranial magnetic stimulation in the treatment of schizophrenic symptoms: a double blind sham controlled study. *J Psychiatr Res*. 2006;40(2):147–152.
 67. Chibbaro G, Daniele M, Alagona G, et al. Repetitive transcranial magnetic stimulation in schizophrenic patients reporting auditory hallucinations. *Neurosci Lett*. 2005;383(1–2):54–57.
 68. Fitzgerald PB. A study of the effectiveness of bilateral transcranial magnetic stimulation in the treatment of the negative symptoms of schizophrenia. *Brain Stimulat*. 2008;1(1):27–32.
 69. Mogg A, Purvis R, Eranti S, et al. Repetitive transcranial magnetic stimulation for negative symptoms of schizophrenia: a randomized controlled pilot study. *Schizophr Res*. 2007;93(1–3):221–228.
 70. Prikryl R, Kasperek T, Skotakova S, et al. Treatment of negative symptoms of schizophrenia using repetitive transcranial magnetic stimulation in a double-blind, randomized controlled study. *Schizophr Res*. 2007;95(1–3):151–157.
 71. Novák T, Horáček J, Mohr P, et al. The double-blind sham-controlled study of high-frequency rTMS (20 Hz) for negative symptoms in schizophrenia: negative results. *Neuroendocrinol Lett*. 2006;27(1–2):209–213.
 72. Hajak G, Marienhagen J, Langguth B, et al. High-frequency repetitive transcranial magnetic stimulation in schizophrenia: a combined treatment and neuroimaging study. *Psychol Med*. 2004;34(7):1157–1163.
 73. Holli MM, Eronen M, Toivonen K, et al. Left prefrontal repetitive transcranial magnetic stimulation in schizophrenia. *Schizophr Bull*. 2004;30(2):429–434.
 74. Klein E, Kolsky Y, Puyerosky M, et al. Right prefrontal slow repetitive transcranial magnetic stimulation in schizophrenia: a double-blind sham-controlled pilot study. *Biol Psychiatry*. 1999;46(10):1451–1454.
 75. Sachdev PS, Loo CK, Mitchell PB, et al. Repetitive transcranial magnetic stimulation for the treatment of obsessive compulsive disorder: a double-blind controlled investigation. *Psychol Med*. 2007;37(11):1645–1649.
 76. Prasko J, Pasková B, Záleský R, et al. The effect of repetitive transcranial magnetic stimulation (rTMS) on symptoms in obsessive compulsive disorder: a randomized, double blind, sham controlled study. *Neuroendocrinol Lett*. 2006;27(3):327–332.
 77. Alonso P, Pujol J, Cardoner N, et al. Right prefrontal repetitive transcranial magnetic stimulation in obsessive-compulsive disorder: a double-blind, placebo-controlled study. *Am J Psychiatry*. 2001;158(7):1143–1145.
 78. Katzman MA, Tricco AC, McIntosh D, et al. Paroxetine versus placebo and other agents for depressive disorders: a systematic review and meta-analysis. *J Clin Psychiatry*. 2007;68(12):1845–1859.
 79. Joffe R, Sokolov S, Streiner D. Antidepressant treatment of depression: a metaanalysis. *Can J Psychiatry*. 1996;41(10):613–616.
 80. Moncrieff J, Wessely S, Hardy R. Active placebos versus antidepressants for depression. *Cochrane Database Syst Rev*. 2004;(1):CD003012.
 81. Moncrieff J, Wessely S, Hardy R. Meta-analysis of trials comparing antidepressants with active placebos. *Br J Psychiatry*. 1998;172(3):227–231, discussion 232–234.
 82. Hermann LL, Ebmeier KP. Transcranial magnetic stimulation. *Physical Treatments*. 2006;5:204–207.
 83. Fitzgerald PB, Benitez J, Daskalakis JZ, et al. The treatment of recurring auditory hallucinations in schizophrenia with rTMS. *World J Biol Psychiatry*. 2006;7(2):119–122.
 84. Poulet E, Brunelin J, Kallel L, et al. Is rTMS efficient as a maintenance treatment for auditory verbal hallucinations? a case report. *Schizophr Res*. 2006;84(1):183–184.
 85. Poulet E, Brunelin J, Kallel L, et al. Maintenance treatment with transcranial magnetic stimulation in a patient with late-onset schizophrenia. *Am J Psychiatry*. 2008;165(4):537–538.
 86. Li X, Nahas Z, Anderson B, et al. Can left prefrontal rTMS be used as a maintenance treatment for bipolar depression? *Depress Anxiety*. 2004;20(2):98–100.
 87. O’Reardon JP, Blumner KH, Peshek AD, et al. Long-term maintenance therapy for major depressive disorder with rTMS. *J Clin Psychiatry*. 2005;66(12):1524–1528.